Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988810 | 0.88 | PPID (0.68) | PPIDSMN1; SMN2ALDH1A1MAPTCA12 | |
| SCHEMBL14531019 | 0.82 | PPID (0.76) | PPIDSMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL4193438 | 0.81 | CA12 (0.56) | PPIDSMN1; SMN2ALDH1A1MAPTCA12 | |
| SCHEMBL14719815 | 0.80 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1KDM4EGAAL3MBTL1 | |
| SCHEMBL734928 | 0.79 | ATM (0.55) | PPIDSMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL14535782 | 0.79 | SYK (0.52) | SMN1; SMN2ALDH1A1MAPTCA12CA1 | |
| SCHEMBL14255755 | 0.79 | EPHX1 (0.56) | PPIDSMN1; SMN2ALDH1A1MAPTCA12 | |
| SCHEMBL28872153 | 0.78 | GAA (0.53) | PPIDSMN1; SMN2CA12CA1CA7 | |
| Hydrochloric Acid SCHEMBL6433307 | 0.78 | ATM (0.53) | PPIDSMN1; SMN2ALDH1A1MAPTCA12 | |
| SCHEMBL4256140 | 0.76 | PPID (0.46) | PPIDSMN1; SMN2CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545683-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2026-02-10 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| CN-115835865-A | CBP/catenin signal transmission path inhibitor and application thereof | 3+2 制药有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4117663-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 Pharma LLC (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA, LLC | 2021-10-14 | — | — | US | disclosed |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA, LLC | 2021-10-14 | — | — | US | disclosed |
| WO-2021183796-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20090215783-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | CHOONGWAE PHARMA CORPORATION (KR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215783-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | CHOONGWAE PHARMA CORPORATION (KR) | 2009-08-27 | — | — | US | disclosed |
| WO-2007139346-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | CHOONGWAE PHARMA CORPORATION (KR) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | PPID 2280/4885SMN1; SMN2 4342/4885ALDH1A1 2132/4885 |
| US-20090215783-A1 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION | MYLK2, TNNC1, MYH2 | PPID 975/4885SMN1; SMN2 103/4885ALDH1A1 648/4885 |
| US-12545683-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, CTNNB1 | PPID 3408/4885SMN1; SMN2 3429/4885ALDH1A1 2182/4885 |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, EP300 | PPID 2280/4885SMN1; SMN2 4342/4885ALDH1A1 2132/4885 |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | PPID 2280/4885SMN1; SMN2 4342/4885ALDH1A1 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.